

Clinical Trial Opportunities

Updated Feb 12, 2021

For more information on our studies call our research line at **416-386-9606** or email **research@memorydisorders.ca**

Alzheimer's Disease Prevention

Eisai AHEAD 3-45 Study (Enrolment Pending)

To determine whether BAN2401 can prevent progression to symptomatic AD in cognitively normal individuals at risk for AD based on PET amyloid accumulation performed as part of the screening for this study. Individuals with sub-threshold and elevated levels of amyloid will be enrolled.

Who: 55-80 years old, cognitively well.

Duration: Treatment for 216 weeks.

Early AD (Mild Cognitive Impairment and Mild AD Dementia)

Eli Lilly TRAILBLAZER-ALZ 2

To evaluate efficacy and safety of donanemab in individuals with early AD.

Who: Individuals 60 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 76 weeks.

Anavex 2-73

To evaluate the efficacy and safety of ANAVEX2-73 in individuals with Early AD.

Who: Individuals 60 to 85 years old with mild dementia due to AD.

Duration: Treatment for up to 48 weeks.

Janssen AUTONOMY (Enrolment Pending)

To evaluate the efficacy and safety of JNJ-63733657 in individuals with early AD.

Who: Individuals 55 to 80 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 4.5 years.

Alector "INVOKE-2"

To assess the safety, tolerability, and efficacy of AL002 in subjects with early Alzheimer's disease.

Who: Individuals 50 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 96 weeks.

Eli Lilly MTAE (Enrolment Pending)

To assess the safety, tolerability, and efficacy of LY3372689 in subjects with early Alzheimer's disease.

Who: Individuals 60 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 124 weeks.

Neuraly NLY01 (Enrolment Pending)

To assess the safety, tolerability, and efficacy of NLY01 in subjects with early Alzheimer's disease.

Who: Individuals 55 to 85 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 72 weeks.

Alzheon ALZ-801 (Enrolment Pending)

To assess the safety, tolerability, and efficacy of ALZ-801 in subjects with early Alzheimer's disease who are homozygous for the E4 variant of the Apolipoprotein E gene.

Who: Individuals 50 to 80 years old with MCI or mild dementia due to AD.

Duration: Treatment for up to 78 weeks.

Mild to Moderate Alzheimer's Dementia

Green Memory

To evaluate the efficacy of oligomannate (GV-971) in treatment of mild to moderate AD.

Who: Individuals 50 to 85 years old with mild to moderate dementia due to AD.

Duration: Treatment for up to 52 weeks. Participants who complete the 52 weeks of treatment may continue into a 26 week Open Label Extension (if eligible).

Cassava (Enrolment Pending)

To assess the safety, tolerability, and efficacy of simufilam (PTI-125) in subjects with mild to moderate Alzheimer's disease.

Who: Individuals 50 to 85 years old with mild to moderate dementia due to AD.

Duration: Treatment up to 12 months.

Moderate to Severe Alzheimer's disease

Vielight

To evaluate the feasibility, safety, and efficacy of Vielight Neuro RX Gamma for the treatment of moderate to severe AD.

Who: Individuals 50+ with moderate to severe Alzheimer's disease.

Duration: Treatment for up to 12 weeks.

Non-Interventional Studies

RetiSpec

RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye.

Who: Individuals 50-90 who are at risk for or those who have pre-clinical Alzheimer's disease or who meet the clinical criteria for MCI and individuals 50-90 who are cognitively normal

Duration: A two-hour session involving photos of the eye using standard eye exam equipment.

Parkinson's Disease Dementia and Lewy Body Dementia Studies

Eisai E2027 (Enrolment Pending)

To assess the safety, tolerability, and efficacy of E2027 in subjects with dementia with Lewy Bodies or Parkinson's disease dementia.

Who: Individuals 50 to 85 years old with LBD or PDD.

Duration: Treatment for 12 weeks.

For more information on our studies call our research line at **416-386-9606** or email research@memorydisorders.ca